TABLE 1.
Antimicrobial activity of ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol against 223 MDR P. aeruginosa isolatesa
| Antimicrobial agent by organism | MIC50 (mg/L) | MIC90 (mg/L) | MIC range (mg/L) | %S | %R |
|---|---|---|---|---|---|
| P. aeruginosa MDR (n = 223) | |||||
| Ceftolozane-tazobactam | 8 | >256 | 1 to >256 | 46.6 | 53.4 |
| Ceftazidime-avibactam | 16 | >256 | 0.5 to >256 | 48.4 | 51.6 |
| Cefiderocol | 0.25 | 1 | 0.016 to 128 | 97.3 | 2.7 |
| P. aeruginosa MDR (n = 85) (carbapenemase positiveb) | |||||
| Ceftolozane-tazobactam | >256 | >256 | 16 to >256 | 0 | 100 |
| Ceftazidime-avibactam | >256 | >256 | 2 to >256 | 3.5c | 96.5 |
| Cefiderocol | 0.5 | 1 | 0.016 to 2 | 100 | 0 |
| P. aeruginosa MDR (n = 138) (carbapenemase negatived) | |||||
| Ceftolozane-tazobactam | 2 | 8 | 1 to >256 | 75.4 | 24.6 |
| Ceftazidime-avibactam | 4 | 32 | 0.5 to >256 | 76.1 | 23.9 |
| Cefiderocol | 0.25 | 2 | 0.016 to 128 | 95.7 | 4.3 |
a
From University Hospital Frankfurt in Germany from 2013 to 2017.
b
Including 81 VIM-producing and 4 GES-5 producing isolates.
c
Represented by 3 GES-5-producing isolates.
d
Including one isolate positive for ESBL-GES-7.